Top

Published in:

01-10-2009 | Original Research Article

Determinant Factors of Osteoporosis Patients’ Reported Therapeutic Adherence to Calcium and/or Vitamin D Supplements

A Cross-Sectional, Observational Study of Postmenopausal Women

Authors: José Sanfelix-Genovés, Prof. Vicente F. Gil-Guillén, Domingo Orozco-Beltran, Vicente Giner-Ruiz, Salvador Pertusa-Martínez, Begoña Reig-Moya, Concepción Carratalá

Published in: Drugs & Aging | Issue 10/2009

Abstract

Background: Among the various treatments for osteoporosis, calcium and/or vitamin D supplements are frequently included.

Objective: The objective of the study was to analyse adherence to calcium and/or vitamin D treatment and to identify related predictors of non-adherence in a sample of postmenopausal women treated for osteoporosis in primary care.

Methods: A cross-sectional, observational study was conducted in a sample of postmenopausal women receiving pharmaceutical treatment for osteoporosis with vitamin D and/or calcium. Sociodemographic, general and osteoporosis-related data were collected. Patient’s perceptions of the adverse effects of treatment, their knowledge of osteoporosis (Batalla test), their attitude towards treatment (Morisky-Green test) and their self-reported therapeutic adherence (Haynes-Sackett test) were assessed.

Results: Of 630 women (mean age ± SD 64.1 ± 8.7 years) evaluated, 36.2% (95% CI 32.4, 39.9) had problems with treatment tolerability, 63.5% (95% CI 59.7, 67.3) had good knowledge of osteoporosis, 20.5% (95% CI 17.3, 23.6) had a good attitude to treatment and 50.0% (95% CI 46.1, 53.9) had good self-reported adherence to treatment. Patients in the poor adherence group had higher mean body mass index (p = 0.014), more concurrent pathologies (p = 0.003), more tolerability problems (p < 0.001) and worse attitude to treatment (p <0.001). The multivariate model showed a positive relationship between therapeutic adherence and good attitude to treatment (odds ratio [OR] = 11.7; p <0.001), not having tolerability problems (OR = 3.3; p <0.001) and no polymedication (OR = 0.80; p = 0.017).

Conclusions: Only one in two postmenopausal women with osteoporosis who take calcium and/or vitamin D have good self-reported therapeutic adherence to this treatment. Determinant factors of adherence to calcium and/or vitamin D treatment were patient’s attitude to the treatment, tolerability problems with the treatment and number of concurrent treatments.

Available only for authorised users

Knobel J, Diez A, Arnau D, et al. Secuelas de la fractura de fémur osteoporótica en Barcelona. Med Clin (Barc) 1992; 98: 441–4

Alvarez-Nebreda ML, Jiménez AB, Rodríguez P, et al. Epidemiology of hip fracture in the elderly in Spain. Bone 2008 Feb; 42(2): 278–85PubMedCrossRef

Altadill Arregui A, Gómez Alonso C, Virgos Soriano MJ, et al. Epidemiología de la fractura de cadera en Asturias. Med Clin (Barc) 1995; 105: 281–6

Herrera A, Martínez AA, Ferrandez L, et al. Epidemiology of osteoporotic hip fractures in Spain. Int Orthop 2006 Feb; 30(1): 11–4PubMedCrossRef

Kanis JA, Torgerson D, Cooper C. Comparison of the European and USA practice guidelines for osteoporosis. Trends Endocrinol Metab 2000; 11: 28–32PubMedCrossRef

Grupo de Trabajo de la Sociedad Española de Investigaciones Óseas y Metabolismo Mineral (SEIOMM). Osteoporosis post-menopáusica: guía de práctica clínica. Rev Clin Esp 2003; 203: 496–506

Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266–81PubMedCrossRef

Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D and calcium to prevent hip fractures in elderly women. N Eng J Med 1992; 327: 1637–42CrossRef

Aranceta J, Serra-Majen L, Pérez-Rodrigo C, et al. Vitamins in Spanish food patterns: the eVe Study. Public Health Nutr 2001; 4: 1317–23PubMed

10.

Ortega RM, Mena MC, Faci M, et al. Vitamin status in different groups of the Spanish population: a meta-analysis of national studies performed between 1990 and 1999. Public Health Nutr 2001; 4: 1325–9PubMed

11.

Vaquero MP, Sánchez-Muniz FJ, Carbajal A, et al. Mineral and vitamin status in elderly persons from northwest Spain consuming an Atlantic variant of the Mediterranean diet. Ann Nutr Metab 2004; 48: 125–33PubMedCrossRef

12.

Van der Wielen RP, Lowik MR, van den Berg H, et al. Serum vitamin D concentrations among elderly people in Europe. Lancet 1995; 346: 207–10PubMedCrossRef

13.

Scharla SH. Prevalence of subclinical vitamin D deficiency in different European countries. Osteoporos Int 1998; 8Suppl. 2: S7–12PubMedCrossRef

14.

Aguado P, delCampo MT, Garcés MV, et al. Low vitamin D levels in outpatient postmenopausal women from a rheumatology clinic in Madrid, Spain: their relationship with bone mineral density. Osteoporos Int 2000; 11: 739–44PubMedCrossRef

15.

Mezquita Raya P, Muñoz Torres M, López Rodríguez F, et al. Elevada prevalencia de déficit de vitamina D en poblaciones con riesgo de osteoporosis: un factor relevante en la integridad ósea. Med Clin (Barc) 2002; 119: 85–9

16.

Larrosa M, Gratacos J, Vaqueiro M, et al. Prevalencia de hipovitaminosis D en una población anciana institucionalizada: valoración del tratamiento sustitutivo. Med Clin (Barc) 2001; 117: 611–4

17.

Gómez-Alonso C, Naves-Díaz ML, Fernández-Martín JL, et al. Vitamin D status and secondary hyperparathyroidism: the importance of 25-hydroxyvitamin D cut-off levels. Kidney Int Suppl 2003 Jun; 63: S44–8CrossRef

18.

Quesada JM, Jans I, Benito P, et al. Vitamin D status of elderly people in Spain. Age Ageing 1989; 18: 392–7PubMedCrossRef

19.

Gaugris S, Heaney RP, Boonen S, et al. Vitamin D inadequacy among post-menopausal women: a systematic review. Q J Med 2005; 98: 667–76CrossRef

20.

McCombs JS, Thiebaud P, McLaughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004; 48: 271–87PubMedCrossRef

21.

Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006; 354: 669–83PubMedCrossRef

22.

Rizzoli R, Boonen S, Brandi ML, et al. The role of calcium and vitamin D in the management of osteoporosis. Bone 2008 Feb; 42(2): 246–9PubMedCrossRef

23.

Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of withdrawal of calcium and vitamin D supplements on bone mass in elderly men and women. Am J Clin Nutr 2000; 72: 745–50PubMed

24.

Kripalan S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med 2007 Mar 26; 167(6): 540–50CrossRef

25.

Gil VF, Belda J, Piñeiro F, et al. El incumplimiento en la práctica clínica: toma de decisiones diagnósticas y terapéuticas. Med Clin (Barc) 2001; 116: 77–87

26.

French MR, Vernace-Inserra F, Hawker GA. A prospective study to identify factors affecting adherence to recommended daily calcium intake in women with low bone mineral density. J Am Coll Nutr 2008 Feb; 27(1): 88–95PubMed

27.

Argimon JM, Jimenez J. Métodos de investigación clínica y epidemiológica. Madrid: Elsevier Ed, 2007

28.

Sackett DL. Compliance trials and the clinician. Arch Intern Med 1978 Jan; 138(1): 23–5PubMedCrossRef

29.

Sackett DL, Haynes RB, Gibson ES. Randomized clinical trial of strategies for improving medication adherence in primary hypertension. Lancet 1975; 1: 1205–7PubMedCrossRef

30.

Haynes RB, Sackett DL, Gibson ES. Improvement of medication adherence in uncontrolled hypertension. Lancet 1976; 1: 1265–8PubMedCrossRef

31.

Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005 Aug 4; 353(5): 487–97PubMedCrossRef

32.

Batalla C, Blanquer A, Ciurana R, et al. Cumplimiento de la prescripción farmacológica en pacientes hipertensos. Aten Primaria 1984; 1: 185–91

33.

Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24: 67–74PubMedCrossRef

34.

Piñeiro Chousa F, Gil Guillén V, Donis Otero M, et al. Validez de 6 métodos indirectos para valorar el cumplimiento del tratamiento farmacológico en las dislipemias. Aten Primaria 1997; 19(9): 465–8

35.

Piñeiro Chousa F, Gil Guillén V, Donis Otero M, et al. Validez de 6 métodos indirectos para valorar el cumplimiento del tratamiento farmacológico en la hipertensión arterial. Aten Primaria 1997; 19(7): 372–6

36.

Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004; 15: 1003–8PubMedCrossRef

37.

Carnevale V, Nieddu L, Romagnoli E, et al. Osteoporosis intervention in ambulatory patients with previous hip fracture: a multicentric, nationwide Italian survey. Osteoporos Int 2006; 17(3): 478–83PubMedCrossRef

38.

Rossini M, Bianchi G, Di Munno O, et al., Treatment of Osteoporosis in clinical Practice (TOP) Study Group. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 2006; 17(6): 914–21PubMedCrossRef

39.

Tang BM, Eslick GD, Nowson C, et al. Calcium and vitamin D for osteoporotic fracture risk. Lancet 2007; 370: 657–66PubMedCrossRef

40.

Yood RA, Mazor KM, Andrade SE, et al. Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs. J Gen Intern Med 2008 Nov; 23(11): 1815–21PubMedCrossRef

41.

McHorney CA, Schousboe JT, Cline RR, et al. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. Curr Med Res Opin 2007 Dec; 23(12): 3137–52PubMedCrossRef

42.

Segal E, Tamir A, Ish-Shalom S. Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J 2003 Dec; 5(12): 859–62PubMed

43.

Papaioannou A, Kennedy CC, Dolovich L, et al. Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging 2007; 24: 37–55PubMedCrossRef

44.

Reginster JY, Rabenda V. Patient preference in the management of postmenopausal osteoporosis with bisphosphonates. Clin Interv Aging 2006; 1(4): 415–23PubMedCrossRef

45.

Kendler D, Kung AW, Fuleihan Gel-H, et al. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 2004 Jul 15; 48(3): 243–51PubMedCrossRef

46.

Lekkerkerker F, Kanis JA, Alsayed N, et al., Group for the Respect of Ethics and Excellence in Science (GREES). Adherence to treatment of osteoporosis: a need for study. Osteoporos Int 2007 Oct; 18(10): 1311–7PubMedCrossRef

47.

Lau E, Papaioannou A, Dolovich L, et al. Patients’ adherence to osteoporosis therapy: exploring the perceptions of postmenopausal women. Can Fam Physician 2008 Mar; 54(3): 394–402PubMed

48.

Giusti A, Barone A, Razzano M, et al. Persistence with calcium and vitamin D in elderly patients after hip fracture. J Bone Miner Metab 2009; 27(1): 95–100PubMedCrossRef

49.

Boonen S, Rizzoli R, Meunier PJ, et al. The need for clinical guidance in the use of calcium and vitamin D in the management of osteoporosis: a consensus report. Osteoporos Int 2004 Jul; 15(7): 511–9PubMedCrossRef

50.

Cranney A, Horsley T, O’Donnell S, et al. Effectiveness and safety of vitamin D in relation to bone health. Evid Rep Technol Assess (Full Rep) 2007 Aug; 158: 1–235

Title: Determinant Factors of Osteoporosis Patients’ Reported Therapeutic Adherence to Calcium and/or Vitamin D Supplements
A Cross-Sectional, Observational Study of Postmenopausal Women
Authors: José Sanfelix-Genovés
Prof. Vicente F. Gil-Guillén
Domingo Orozco-Beltran
Vicente Giner-Ruiz
Salvador Pertusa-Martínez
Begoña Reig-Moya
Concepción Carratalá
Publication date: 01-10-2009
Publisher: Springer International Publishing
Published in: Drugs & Aging / Issue 10/2009
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI: https://doi.org/10.2165/11317070-000000000-00000

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2009

Vulvar Lichen Sclerosus in the Elderly

Sedative Load and Mortality among Residents of Long-Term Care Facilities

Medication Use and Increased Risk of Falls in Hospitalized Elderly Patients

Effects of Potentially Inappropriate Psychoactive Medications on Falls in US Nursing Home Residents

Novel Therapies for Pemphigus Vulgaris

Pregabalin

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials